BMY241101P49000
- 0.16
- +0.03+23.08%
Bristol-Myers Squibb Newsroom
Bristol-Myers Squibb Analyst Ratings
Citi Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Cuts Target Price to $55
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $53
Bristol-Myers Squibb: Navigating Financial Adjustments and Competitive Pressures Amidst a Hold Rating
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $43
Barclays Sticks to Their Sell Rating for Bristol-Myers Squibb (BMY)
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
BMO Capital raises bristol-myers squibb's target price to $53.
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60